Non-Executive Chairman and Member of Governance and Nominating Committee
Mr. William U. Parfet is NonExecutive Independent Chairman of the Board of Stryker Corporationration, since February 8, 2012. He has served as Chairman and Chief Executive Officer of MPI Research, Inc., a drug safety and pharmaceutical development company, since 1999. He is also a director of Monsanto Company, a provider of agricultural products that improve farm productivity, and Taubman Centers, Inc., a real estate development company.
The company has Return on Asset of 8.43 % which means that on every $100 spent on asset it made $8.43 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.2 % implying that it generated $15.2 on every 100 dollars invested.
The company has 2.77 B in debt with debt to equity (D/E) ratio of 0.33 which is OK given its current industry classification. Stryker Corporation has Current Ratio of 4.57 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.
Stryker Corporationration, a medical technology company, offer reconstructive, medical and surgical, and neurotechnology and spine solutions for doctors, hospitals, and other healthcare facilities. Stryker Corporation [SYK] is traded on New York Stock Exchange in USA. It is located in Kalamazoo, MI and employs 22,010 people. Filter other
Click "OK" to permanently delete this portfolio. Click "Cancel" if you have changed your mind.
Report was successfully generated
You can either (1) right-mouth click the image to download it to your local drive or simply (2) copy and paste the
image data below to include picture of this graph on your web page without downloading the image file
Copy and paste above text right to your web page html
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory